Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 7707 results

  1. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808

    Awaiting development [GID-TA11200] Expected publication date: TBC

  2. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development [GID-TA11219] Expected publication date: TBC

  3. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822

    Awaiting development [GID-TA11229] Expected publication date: TBC

  4. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease TS ID 11791

      Status ...

  5. Social work interventions for adults with complex needs (including learning disabilities) and mental health needs

    Awaiting development [GID-QS10148] Expected publication date: TBC

  6. Readmission to ICU within 48hrs

    Awaiting development [GID-QS10105] Expected publication date: TBC

  7. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 TS ID 11807

      Status ...

  8. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828

      Status ...

  9. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

    Awaiting development [GID-TA11275] Expected publication date: TBC

  10. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839

    Awaiting development [GID-TA11276] Expected publication date: TBC

  11. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190

    Awaiting development [GID-TA11283] Expected publication date: TBC

  12. CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666

    Awaiting development [GID-TA11182] Expected publication date: TBC

  13. DV7103 for treating cystinuria in people 6 months and over TS ID 10438

      Status ...